DALLAS and FORT WORTH, Texas, Feb.
20, 2018 /PRNewswire/ -- Neos Therapeutics, Inc. (Nasdaq:
NEOS), a pharmaceutical company focused on developing,
manufacturing and commercializing innovative extended-release (XR)
products using its proprietary modified-release drug delivery and
orally disintegrating tablet (ODT) technologies, issued the
following statement in response to the announcement from PDL
BioPharma, Inc. (NASDAQ: PDLI) that it is terminating its interest
in the Company:
"The Neos Board of Directors and management team are confident
in the Company's strategic plan and believe that Neos is well
positioned for significant value creation in both the near and
long-term. We are successfully executing our strategy, as
demonstrated by the continued strong adoption of Adzenys
XR-ODT®, the successful launch of Cotempla
XR-ODT™ earlier this year and the imminent
commercial launch of Adzenys ER™. We are
equally excited about the future opportunities afforded by our
proprietary extended-release drug delivery technology
platform. We are committed to serving the best interest of
all Neos shareholders and remain open to considering all options to
deliver on the Board and management's value creation
objectives."
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical
company focused on developing, manufacturing and commercializing
products utilizing its proprietary modified-release drug delivery
technology platforms. Adzenys XR-ODT® (amphetamine)
extended-release orally disintegrating tablets (see Full
Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™
(methylphenidate) extended-release orally disintegrating tablets
(see Full Prescribing Information, including Boxed WARNING), and
Adzenys-ER™ (amphetamine) extended-release oral suspension (see
Full Prescribing Information, including Boxed WARNING), all for the
treatment of ADHD, are the first three approved products using the
Company's extended-release technology platform. In addition,
Neos manufactures and markets its generic version of the branded
product Tussionex®1, an extended-release oral suspension
of hydrocodone and chlorpheniramine for the relief of cough and
upper respiratory symptoms of a cold (see Full Prescribing
Information, including Boxed WARNING). Additional information about
Neos is available at www.neostx.com.
1Tussionex® is a registered trademark of
the UCB Group of Companies.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or our future financial or operating performance. In some cases,
you can identify forward-looking statements because they contain
words such as "may," "will," "should," "expects," "plans,"
"anticipates," "could," "intends," "target," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these words or other similar terms or
expressions that concern our expectations, strategy, plans or
intentions. These forward-looking statements reflect our current
views about our expectations, strategy, plans, near and long-term
value creation opportunities, which are based on the information
currently available to us and on assumptions we have made. Although
we believe that our plans, intentions, expectations, strategies and
prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, our ability to market and
sell our product candidates and other risks set forth under the
caption "Risk Factors" in our most recently filed Annual Report on
Form 10-K as updated by our subsequently filed other SEC filings,
including our Quarterly Report(s) on Form 10-Q. We assume no
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise.
Contacts:
Media:
Barrett Golden and Andrew Squire
Joele Frank, Wilkinson Brimmer
Katcher
(212) 355-4449
Investors:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
View original
content:http://www.prnewswire.com/news-releases/neos-therapeutics-reiterates-confidence-in-strategic-plan-and-value-creation-opportunities-300601185.html
SOURCE Neos Therapeutics, Inc.